The BLASST-1 study presented at the 2022 ASCO Genitourinary Cancers Symposium assessed the safety and efficacy of neoadjuvant nivolumab in combination with gemcitabine/cisplatin in patients with muscle-invasive bladder cancer .
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
“We look forward to announcing initial efficacy and safety data from the study, which we expect will be at the end of this quarter,” says…
“I think that this field is going to continue to evolve, especially when we think about how to incorporate PSMA-PET findings into our clinical care,”…
“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further…
“I think the greatest implication the study has is that it tells us that family history and germline genetics independently provide complementary information that’s important…
The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of…
“There are plenty of articles written about stress-induced urgency. I, at the time, only found 1 article written in the gynecologic literature about what they…
“We can also look at the timing of exposure to urology. Does early exposure spark interest in urology, or does delayed introduction to the field…
“We are hopeful that this therapy will help patients with prostate cancer and that this study will be just the first step towards the effective…
“In my view, at present in patients that have low-volume oligometastatic de novo metastatic prostate cancer, it’s really an unknown whether comprehensive SBRT or other…
